Evidence map›Paper›PMID 38301089›Full record

ArticleArchives of Iranian medicine2023

Influence of HLA-A, -B, -DR Polymorphisms on the Severity of COVID-19: A Case-Control Study in the Iranian Population.

Parisa Mashayekhi, Mir Davood Omrani, Zeynab Yassin, Ali Dehghanifard, Leila Ashouri, Sara Sadat Aghabozorg Afjeh, Zahra Shabanzadeh

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of Iranian medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Parisa MashayekhiMolecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.ORCID 0000-0002-6373-3266
Mir Davood OmraniUrogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-0673-9717
Zeynab YassinAntimicrobial resistance Research Center, Institute Of Immunology And Infectious Disease, Iran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-1915-6596
Ali DehghanifardMolecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Leila AshouriAntimicrobial resistance Research Center, Institute Of Immunology And Infectious Disease, Iran University of Medical Sciences, Tehran, Iran.
Sara Sadat Aghabozorg AfjehDepartment of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-6352-9310
Zahra ShabanzadehMolecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Pasteur Institute of Iran · IRIran University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs an emerging pandemic disease, COVID-19 encompasses a spectrum of clinical diagnoses, from the common cold to severe respiratory syndrome. Considering the shreds of evidence demonstrating the relationship between human leukocyte antigen (HLA) allele diversity and infectious disease susceptibility, this study was conducted to determine the association of HLA alleles with COVID-19 severity in Iranian subjects.

methodsIn this case-control study, a total of 200 unrelated individuals (consisting of 100 people with severe COVID-19 and an average age of 55.54 as the case group, and 100 patients with mild COVID-19 with an average age of 48.97 as the control group) were recruited, and HLA typing (Locus A, B, and DR) was performed using the Olerup sequence-specific oligonucleotide (SSO) HLA-typing kit.

resultsOur results showed that HLA-A*11 and HLA-DRB1*14 alleles were more frequently observed in severe COVID-19 cases, while HLA-B*52 was more common in mild cases, which was in agreement with some previous studies.

conclusionOur results confirmed the evidence for the association of HLA alleles with COVID-19 outcomes. We found that HLA-A*11 and HLA-DRB1*14 alleles may be susceptibility factors for severe COVID-19, while HLA-B*52 may be a protective factor. These findings provide new insight into the pathogenesis of COVID-19 and help patient management.

Indexed as

COVID-19Genetic Predisposition to DiseaseHLA-A AntigensHLA-B AntigensHLA-DRB1 ChainsAllelesCase-Control StudiesGene FrequencyHaplotypesHumansIranMiddle AgedPatient AcuityHLA-A AntigensHLA-B AntigensHLA-DRB1 ChainsCOVID-19HLASusceptibility

Identifiers

PMID38301089
PMCPMC10685865
OpenAlexW4386105618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.